Open AccessA Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma
Author(s) -
Dina Farinha,
Michael T. Migawa,
Ana Bela SarmentoRibeiro,
Henrique Faneca
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s302288
Subject(s) - flow cytometry , cancer research , programmed cell death , cancer cell , nanocarriers , apoptosis , viability assay , context (archaeology) , drug delivery , materials science , chemistry , biophysics , cancer , biology , microbiology and biotechnology , nanotechnology , biochemistry , paleontology , genetics
Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death. Sorafenib, which is the first-line therapy for this disease, is associated with reduced therapeutic efficacy that could potentially be overcome by combination with selumetinib. In this context, the main goal of this work was to develop a new nanosystem, composed of a polymeric core coated by a lipid bilayer containing the targeting ligand GalNAc, to specifically and efficiently co-deliver both drugs into HCC cells, in order to significantly increase their therapeutic efficacy.